Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Efficacy and Safety of Rasburicase for the Treatment/Prevention of Hyperuricemia Related to Tumor Lysis Syndrome in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma, Previously Treated or Not With Urate Oxidase Presenting With Hyperuricemia and/or Bulky Disease

NCT00664144 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00664144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00664144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Efficacy and Safety of Rasburicase for the Treatment/Prevention of Hyperuricemia Related to Tumor Lysis Syndrome in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma, Previously Treated or Not With Urate Oxidase Presenting With Hyperuricemia and/or Bulky Disease
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2002
Completion date
January 31, 2005
Enrollment
33 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia